INTRODUCTION
Tightly controlling T cell activation is crucial to the prevention of autoimmune diseases and lymphoproliferative syndromes. T cells become activated following recognition by the TCR of antigenic peptides presented by MHC molecules on APCs, concurrently to the ligation of costimulatory receptors. CD28, the prototype of T cell costimulatory receptors, is constitutively expressed on T cells and binds B7-1 (CD80) and B7-2 (CD86) on APCs [1] . Once activated, T cells upregulate several surface receptors that, when engaged, limit immune responses by inducing either cell-cycle arrest or apoptosis. This is thought to be essential to prevent uncontrolled progressive lymphoaccumulation. CTLA-4 is one such inhibitory receptor that is transiently expressed after T cell activation. Like CD28, CTLA-4 binds B7-1 and B7-2, albeit with a higher affinity than CD28 [1] . Thus, it is thought that endogenous CTLA-4 can inhibit T cell responses both by preventing CD28 from binding its ligands as well as by directly inhibiting TCR signaling [2, 3] .
Consistent with the inhibitory role of CTLA-4, CTLA-4-deficiency in mice results in a severe lymphoproliferative disorder and an autoimmune disease that leads to early animal death [4, 5] . Similarly, blockade of CTLA-4 engagement following administration of anti-CTLA-4 mAbs in vivo leads to increased severity of disease in mouse models of autoimmunity, such as diabetes [6] and experimental autoimmune encephalopathy [7] . Thus, the converse approach of augmenting CTLA-4 signaling would be desirable to inhibit immune responses in settings of autoimmune diseases or of transplant rejection. However, few reagents to date can cross-link CTLA-4 in vivo and elicit its negative regulatory effect on T cell function. We have previously shown that expression of a membrane-bound single chain anti-CTLA-4 mAb on a tumor cell-line effectively engaged CTLA-4 and led to reduced allogeneic tumor rejection when these tumor cells were inoculated into MHC-mismatched recipients [8] . These results indicate that endogenous CTLA-4 can be cross-linked more effectively than what normally occurs during antigen encounter in vivo, resulting in significantly dampened immune responses.
In this study, we explored the possibility that increasing the expression levels of CTLA-4 and having its expression be constitutive rather than induced in T cells may also result in further inhibition of T cell responses. CTLA-4 transgenic (CTLA-4-Tg) mice that constitutively express a CTLA-4 transgene in addition to the inducible endogenous CTLA-4 were previously generated [9] . When crossed with CTLA-4- deficient mice, these transgenic animals were free of detectable lymphoproliferation and autoimmunity, indicating that expression of the transgene could replace that of endogenous CTLA-4. Thus, although transgenic expression of CTLA-4 in T cells reduced the severity of spontaneously occurring autoimmune diseases, it was not clear whether it would also reduce T cell responses after exogenous antigenic challenge. In addition, the autoimmune disease models could not distinguish whether the inhibitory effects of constitutive CTLA-4 overexpression were due to B7 scavenging away from CD28, or to intrinsic inhibitory properties of the transgene. Indeed, treatment of CTLA-4-deficient mice from birth with soluble CTLA-4-Ig that blocked CD28 ligation is sufficient to prevent disease [10] . In this study, we investigated whether constitutive expression of CTLA-4 can inhibit T cell activation in settings of CD28-sufficiency and -deficiency in vivo. 
METHODS

Mice
Flow cytometry analysis
To determine the intracellular DNA content, CD4
＋ and For cell proliferation analysis, CD28-KO and CTLA-4-Tg/ CD28-KO T cells enriched by negative selection were labeled with CFSE. Briefly, 5×10 6 cells were washed once and resuspended in PBS at a concentration of 2×10 7 /ml. An equal volume of a CFSE (Molecular Probes, Eugene, OR) solution (5 μM in PBS) was added and cells were incubated at room temperature for 9 minutes. The reaction was quenched by the addition of 5 ml of FCS for 1 minute. Cells were then washed twice in complete medium and stimulated as above. Cells were harvested at different time points, stained with PE coupled anti-CD4 or anti-CD8 mAbs (BD/PharMingen).
GVHD model
BALB/c mice were sub-lethally irradiated (650 rads). After 24 h, the animals received an intravenous injection of CD28-KO or CTLA-4-Tg/CD28-KO T cells (4∼6×10 6 cells/ mouse) that had been purified by negative selection and labeled with CFSE as described above. The animals were sacrificed on day 2 and spleens were harvested. Splenocytes were labeled with PE-coupled anti-K b and APC-coupled antiThy1.2, CD4 or CD8 (BD/Pharmingen) and analyzed by flow cytometry. Events were gated on
＋ cells and CFSE fluorescence intensity was measured.
RESULTS
Overexpression of CTLA-4 in T cells results in reduced responses of T cells in vitro
To 
CTLA-4-Tg T cells display reduced cell-cycle progression and increased death upon TCR stimulation
Decreased anti-CD3-dependent 3 H-thymidine incorporation could be the consequence of reduced T cell-cycle progression or of augmented T cell death. In addition, it was possible that APCs from CTLA-4-Tg mice had reduced antigen presentation or costimulatory capacity because of chronic exposure to CTLA-4. Therefore, to assess the capacity of T cells to progress through the cell-cycle, CD4
＋ T cells were purified from WT and CTLA-4-Tg splenocytes and stimulated with anti-CD3 mAb. To normalize the APCs in the system, irradiated T-depleted syngeneic WT splenocytes (syngeneic APCs) were used. T cells were then subjected to intracellular PI staining at different time points after stimulation. As shown in To confirm that expression of the CTLA-4 transgene resulted in increased T cell death, purified T cells were stimu- ). Animals were sacrificed on day 2 and division of transferred T cells was analyzed by flow cytometry. Reduced expansion of CTLA-4-Tg/CD28-KO T cells than CD28-KO T cells was observed both in CD4 ＋ and CD8 ＋ T cells (Fig. 4) . This result indicates that overexpression of CTLA-4 can downregulate T cell responses independent of CD28 expression in vivo.
DISCUSSION
Our study shows that enhancing the level of expression of CTLA-4 in T cells can result in reduced T cell responses both in vitro and in vivo.
CTLA-4 has been widely used as an immunological target in experimental tumor models since its blockade, following systemic administration of an anti-CTLA-4 mAb, was reported to augment immune responses [11] . Two clinical trials using this approach were recently released and showed promising results as preventing CTLA-4 engagement in tumor patients was demonstrated to augment T cell responses, and, in some cases, lead to partial or complete tumor regression [12, 13] . In contrast, finding means to mimic the inhibitory function of CTLA-4 in vivo, as a therapeutic method to attenuate or prevent autoimmune flairs or transplant rejection episodes, has proven elusive. The approaches that we and others have published to date are based on transforming blocking anti-CTLA-4 mAbs into agonistic mAbs by use of bi-specificity [14, 15] or plasma membrane immobilization [8] , or by membrane-immobilizing a mutated form of B7-1 that binds CTLA-4 but not CD28 [16] . In this study, we have examined whether forcing constitutive high levels of CTLA-4 expression in T cells is sufficient to downregulate immune responses. Previous work from Fecteau and colleagues has shown that upregulation of endogenous CTLA-4 may be one of the mechanisms responsible for tolerance after administration of anti-CD45RB mAb in a mouse transplant model [17] , suggesting that enhancing CTLA-4 expression in T cells may be a valid approach to inhibit T cell responses. Our current work supports these conclusions and indicates that genetically forcing expression of CTLA-4 such that it is expressed constitutively in all T cells results in further inhibition of T cell immune responses.
Whereas it is clear that engagement of endogenous CTLA-4 can induce cell-cycle arrest by inhibitin cyclin D3, CDK4 and CDK6 [18] , whether CTLA-4 ligation induces T cell death is more controversial. Only two reports to date have supported apoptosis of human or mouse T cells after engagement of endogenous CTLA-4 in activated T cells [19, 20] . In contrast, engagement of CTLA-4 was reported to block CD95-mediated cell death [21] and to maintain T cell survival by allowing TCR-mediated expression of BclxL [22] . Our results suggest that constitutive expression of CTLA-4 can result in increased T cell death. Whether this is due to growth factor deprivation as engagement of CTLA-4 results in reduced cytokine production by T cells, or to increased susceptibility to apoptosis downstream of death receptors remains to be investigated.
It has been previously shown that endogenous CTLA-4 can function in a CD28 independent manner, as blockade of CTLA-4 in vivo results in accelerated heart allograft rejection in CD28-deficient mice [2] . Also, it has been reported that CTLA-4 could inhibit T cell function in the absence of CD28 [23] . There has been a contrasting report however, that CTLA-4 overexpression is unable to attenuate immune responses in the absence of CD28 [24] . We have previously shown that T cells in CTLA-4-Tg/CD28-KO mice exhibit lower proliferation levels compared to their counterparts in CD28-KO mice without regard to IL-2 concentrations [25] . Our results in this current study indicates that constitutive transgenic expression of CTLA-4 can also inhibit T cell responses independently of CD28 expression in vivo, even though its constitutive expression would be expected to efficiently prevent CD28 ligation to B7. One possibility is that B7 scavenging from CD28 is not very efficient in naive T cells because the cellular distribution of the CTLA-4 transgene is similar to that of endogenous CTLA-4 after T cell activation. Most of the CTLA-4 molecules are found in intracellular compartments and very few molecules are displayed on the T cell surface at any given point (data not shown). As the CTLA-4 transgene comprises the same cytoplasmic tail as the endogenous protein, it is likely that it will follow the same rules. The motif surrounding tyrosine
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201 enables CTLA-4 to bind to the clathrin adaptor AP-50, resulting in rapid endocytosis from the cell surface [26, 27] . This process is prevented transiently when tyrosine 201 is phosphorylated following TCR stimulation, leading to increased CTLA-4 surface accumulation [28] . Therefore, it is likely that the CTLA-4 transgene on naive T cells may not bind B7 molecules very effectively despite its high affinity for B7 family members.
We have recently shown that the CTLA-4 transgene can prevent lymphoproliferation and autoimmunity in IL-2-deficient mice, an autoimmune model with reduced CTLA-4 expression in T cells [25] . These results had suggested that augmenting CTLA-4 expression in T cells could have clinical application potential in autoimmune situations of deficient CTLA-4 upregulation. Our current study suggests that augmenting CTLA-4 expression in T cells may be an attractive strategy to reduce T cell responses in autoimmunity or transplantation settings, even if endogenous expression of CTLA-4 is normal.
